These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21698356)

  • 1. Targeting myeloma-osteoclast interaction with Vγ9Vδ2 T cells.
    Cui Q; Shibata H; Oda A; Amou H; Nakano A; Yata K; Hiasa M; Watanabe K; Nakamura S; Miki H; Harada T; Fujii S; Kagawa K; Takeuchi K; Ozaki S; Matsumoto T; Abe M
    Int J Hematol; 2011 Jul; 94(1):63-70. PubMed ID: 21698356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion.
    Abe M; Hiura K; Wilde J; Shioyasono A; Moriyama K; Hashimoto T; Kido S; Oshima T; Shibata H; Ozaki S; Inoue D; Matsumoto T
    Blood; 2004 Oct; 104(8):2484-91. PubMed ID: 15187021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic acid and interleukin-2 treatment improves immunocompetence in HIV-infected persons by activating Vgamma9Vdelta2 T cells.
    Poccia F; Gioia C; Martini F; Sacchi A; Piacentini P; Tempestilli M; Agrati C; Amendola A; Abdeddaim A; Vlassi C; Malkovsky M; D'Offizi G
    AIDS; 2009 Mar; 23(5):555-65. PubMed ID: 19238075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
    Benzaïd I; Mönkkönen H; Stresing V; Bonnelye E; Green J; Mönkkönen J; Touraine JL; Clézardin P
    Cancer Res; 2011 Jul; 71(13):4562-72. PubMed ID: 21646473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adoptive transfer of ex vivo expanded Vγ9Vδ2 T cells in combination with zoledronic acid inhibits cancer growth and limits osteolysis in a murine model of osteolytic breast cancer.
    Zysk A; DeNichilo MO; Panagopoulos V; Zinonos I; Liapis V; Hay S; Ingman W; Ponomarev V; Atkins G; Findlay D; Zannettino A; Evdokiou A
    Cancer Lett; 2017 Feb; 386():141-150. PubMed ID: 27865798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ex vivo expansion and activation of Vγ9Vδ2 T cells by CELMoDs in combination with zoledronic acid.
    Inoue Y; Oda A; Maeda Y; Sumitani R; Oura M; Sogabe K; Maruhashi T; Takahashi M; Fujii S; Nakamura S; Miki H; Hiasa M; Teramachi J; Harada T; Abe M
    Int J Hematol; 2024 Jun; 119(6):626-630. PubMed ID: 38581458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vγ9Vδ2 T cells, αβ CD8+ T cells, regulatory T cells, and dendritic cells.
    Castella B; Riganti C; Fiore F; Pantaleoni F; Canepari ME; Peola S; Foglietta M; Palumbo A; Bosia A; Coscia M; Boccadoro M; Massaia M
    J Immunol; 2011 Aug; 187(4):1578-90. PubMed ID: 21753152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of the antitumor activity of human Vγ9Vδ2 T cells in combination with zoledronic acid in a preclinical model of neuroblastoma.
    Di Carlo E; Bocca P; Emionite L; Cilli M; Cipollone G; Morandi F; Raffaghello L; Pistoia V; Prigione I
    Mol Ther; 2013 May; 21(5):1034-43. PubMed ID: 23481325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro expansion of gamma delta T cells with anti-myeloma cell activity by Phosphostim and IL-2 in patients with multiple myeloma.
    Burjanadzé M; Condomines M; Reme T; Quittet P; Latry P; Lugagne C; Romagne F; Morel Y; Rossi JF; Klein B; Lu ZY
    Br J Haematol; 2007 Oct; 139(2):206-16. PubMed ID: 17897296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma.
    Mariani S; Muraro M; Pantaleoni F; Fiore F; Nuschak B; Peola S; Foglietta M; Palumbo A; Coscia M; Castella B; Bruno B; Bertieri R; Boano L; Boccadoro M; Massaia M
    Leukemia; 2005 Apr; 19(4):664-70. PubMed ID: 15744346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expansion With IL-15 Increases Cytotoxicity of Vγ9Vδ2 T Cells and Is Associated With Higher Levels of Cytotoxic Molecules and T-bet.
    Aehnlich P; Carnaz Simões AM; Skadborg SK; Holmen Olofsson G; Thor Straten P
    Front Immunol; 2020; 11():1868. PubMed ID: 32983105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Large-scale expansion of Vγ9Vδ2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells.
    Xiao L; Chen C; Li Z; Zhu S; Tay JC; Zhang X; Zha S; Zeng J; Tan WK; Liu X; Chng WJ; Wang S
    Cytotherapy; 2018 Mar; 20(3):420-435. PubMed ID: 29402645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients.
    Meraviglia S; Eberl M; Vermijlen D; Todaro M; Buccheri S; Cicero G; La Mendola C; Guggino G; D'Asaro M; Orlando V; Scarpa F; Roberts A; Caccamo N; Stassi G; Dieli F; Hayday AC
    Clin Exp Immunol; 2010 Aug; 161(2):290-7. PubMed ID: 20491785
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells.
    Zhuang J; Zhang J; Lwin ST; Edwards JR; Edwards CM; Mundy GR; Yang X
    PLoS One; 2012; 7(11):e48871. PubMed ID: 23173040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vγ9Vδ2 T cells inhibit immature dendritic cell transdifferentiation into osteoclasts through downregulation of RANK, c‑Fos and ATP6V0D2.
    Zhu X; Zeng Z; Qiu D; Chen J
    Int J Mol Med; 2018 Oct; 42(4):2071-2079. PubMed ID: 30066839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP.
    Roelofs AJ; Jauhiainen M; Mönkkönen H; Rogers MJ; Mönkkönen J; Thompson K
    Br J Haematol; 2009 Jan; 144(2):245-50. PubMed ID: 19016713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vγ9Vδ2 T cells.
    Dhar S; Chiplunkar SV
    Cancer Immun; 2010 Nov; 10():10. PubMed ID: 21069948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells.
    Arkko S; Zlatev HP; Mönkkönen H; Räikkönen J; Benzaïd I; Clézardin P; Mönkkönen J; Määttä JA
    Cancer Lett; 2015 Feb; 357(1):279-285. PubMed ID: 25444923
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin.
    Tanaka Y; Abe M; Hiasa M; Oda A; Amou H; Nakano A; Takeuchi K; Kitazoe K; Kido S; Inoue D; Moriyama K; Hashimoto T; Ozaki S; Matsumoto T
    Clin Cancer Res; 2007 Feb; 13(3):816-23. PubMed ID: 17289872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo.
    Dieli F; Gebbia N; Poccia F; Caccamo N; Montesano C; Fulfaro F; Arcara C; Valerio MR; Meraviglia S; Di Sano C; Sireci G; Salerno A
    Blood; 2003 Sep; 102(6):2310-1. PubMed ID: 12959943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.